The Hematology Research Training Program at the University of Pennsylvania was established in 1978 and currently supports 8 postdoctoral trainees per year. Since its inception 24 years ago, the goal of our program has been to identify individuals interested in the broadly-defined discipline of hematology, and to help them prepare for academic careers as independent investigators using their scientific training in basic, translational and patient-oriented research. Originally the candidates were drawn almost exclusively from physicians enrolled in the clinical hematology-oncology training programs in the Departments of Medicine and Pediatrics, but as specified at the time of the last renewal, we have deliberately sought non-physician postdoctoral trainees in order to provide a mix of backgrounds and interests. During the first 24 years of 'funding, 87 postdoctoral trainees and one pre-doctoral trainee have been supported: 63 M.D., 12 M.D.-Ph.D. and 12 Ph.D. Twenty five of the trainees are women and 63 are men. Of the 77 trainees who have completed training, 47 (61%) hold full-time appointments at an academic institution and are engaged in either laboratory or clinical research. An additional 7 (9%) are engaged primarily in clinical practice, but have university appointments and participate in clinical research projects and teaching part-time. Thirty four of our former trainees who have completed training have extramural research funding. Thirty nine hold faculty appointments at 24 institutions, including Penn, Harvard and the NIH. Although historically this program has supported postdoctoral trainees almost exclusively, we now seek added support in order to appoint up to 4 predoctoral trainees per year. These additional trainees will be drawn primarily from physician-scientist trainees in Penn's MD-PhD program - a program that is also directed by Lawrence Brass, the principal investigator on this grant. The addition of predoctoral students to our program reflects our belief in the long term value of attracting talented students in hematology-related research at an earlier point in their training. A detailed plan for identifying appropriate pre- and postdoctoral candidates, providing them with the research and laboratory skills needed for an independent career, and mentoring them throughout the process is included in the application.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
2T32HL007439-26
Application #
6745393
Study Section
Special Emphasis Panel (ZHL1-CSR-G (F1))
Program Officer
Chang, Henry
Project Start
1979-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
26
Fiscal Year
2004
Total Cost
$752,088
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brenner, Jacob S; Kiseleva, Raisa Yu; Glassman, Patrick M et al. (2018) The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulm Circ 8:2045893217752329
Bagashev, Asen; Sotillo, Elena; Tang, Chih-Hang Anthony et al. (2018) CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol :
Greineder, Colin F; Villa, Carlos H; Walsh, Landis R et al. (2018) Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjug Chem 29:56-66
Kiseleva, Raisa Yu; Glassman, Patrick M; Greineder, Colin F et al. (2018) Targeting therapeutics to endothelium: are we there yet? Drug Deliv Transl Res 8:883-902
Greineder, Colin F; Johnston, Ian H; Villa, Carlos H et al. (2017) ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Adv 1:1452-1465
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
George, Lindsey A; Sullivan, Spencer K; Giermasz, Adam et al. (2017) Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 377:2215-2227
Zhen, Tao; Kwon, Erika M; Zhao, Ling et al. (2017) Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. Blood 130:2431-2442
Peslak, Scott A; Olson, Timothy; Babushok, Daria V (2017) Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol 18:70
Carnemolla, Ronald; Villa, Carlos H; Greineder, Colin F et al. (2017) Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31:761-770

Showing the most recent 10 out of 118 publications